Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
Status:
WITHDRAWN
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Anemia is a common complication among cancer patients and is negatively associated with overall prognosis and therapeutic outcomes. The purpose of this study is to see if giving a dose of iron prior to any standard of care chemotherapy treatment will affect the cells that are believed to make treating melanoma harder, making melanoma more responsive to the standard of care immunotherapy.